• Elicera Therapeutics AB received a notice of allowance from the Japan Patent Office for a patent covering oncolytic virus candidate ELC-201.
• The Japan patent would provide exclusive rights to develop and sell ELC-201-based cancer treatments in Japan, once granted.
• The protection targets engineered oncolytic viruses designed to boost immune responses, supporting development of ELC-201 for solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202609010806BITN____UKPR__EN_20260901-BIT-5004-0) on September 01, 2026, and is solely responsible for the information contained therein.